Balyasny Asset Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $568K | Buy |
2,898
+1,203
| +71% | +$234K | ﹤0.01% | 2317 |
|
|
2025
Q4 | $294K | Sell |
1,695
-219,808
| -99% | -$40M | ﹤0.01% | 2734 |
|
|
2025
Q3 | $42.2M | Buy |
+221,503
| New | +$39.3M | 0.05% | 421 |
|
|
2025
Q2 | – | Sell |
-207,256
| Closed | -$35.1M | – | 2934 |
|
|
2025
Q1 | $35.1M | Buy |
207,256
+94,693
| +84% | +$15.6M | 0.06% | 404 |
|
|
2024
Q4 | $17M | Sell |
112,563
-67,049
| -37% | -$10.4M | 0.03% | 740 |
|
|
2024
Q3 | $27.9M | Sell |
179,612
-213,444
| -54% | -$31.9M | 0.05% | 510 |
|
|
2024
Q2 | $53.8M | Buy |
+393,056
| New | +$53.8M | 0.09% | 275 |
|
|
2023
Q3 | – | Sell |
-529,467
| Closed | -$74.4M | – | 2348 |
|
|
2023
Q2 | $74.4M | Buy |
+529,467
| New | +$73M | 0.16% | 150 |
|
|
2022
Q4 | – | Sell |
-110,853
| Closed | -$13.6M | – | 2868 |
|
|
2022
Q3 | $13.6M | Sell |
110,853
-478,006
| -81% | -$63M | 0.04% | 561 |
|
|
2022
Q2 | $78.3M | Buy |
588,859
+573,216
| +3,664% | +$78.1M | 0.25% | 73 |
|
|
2022
Q1 | $2.14M | Buy |
+15,643
| New | +$2.18M | 0.01% | 1323 |
|
|
2020
Q3 | – | Sell |
-384,222
| Closed | -$45.4M | – | 1356 |
|
|
2020
Q2 | $43.8M | Buy |
+384,222
| New | +$40.8M | 0.38% | 49 |
|
|
2020
Q1 | – | Sell |
-72,433
| Closed | -$7.74M | – | 1225 |
|
|
2019
Q4 | $7.74M | Sell |
72,433
-345,686
| -83% | -$36M | 0.05% | 491 |
|
|
2019
Q3 | $44.8M | Sell |
418,119
-228,618
| -35% | -$23.5M | 0.31% | 79 |
|
|
2019
Q2 | $65.8M | Buy |
646,737
+571,015
| +754% | +$54.9M | 0.42% | 44 |
|
|
2019
Q1 | $6.81M | Buy |
+75,722
| New | +$6.56M | 0.05% | 492 |
|
|
2018
Q4 | – | Sell |
-227,374
| Closed | -$24.5M | – | 1465 |
|
|
2018
Q3 | $24.5M | Buy |
227,374
+225,121
| +9,992% | +$24.7M | 0.11% | 252 |
|
|
2018
Q2 | $248K | Sell |
2,253
-539,267
| -100% | -$56.2M | ﹤0.01% | 1574 |
|
|
2018
Q1 | $54.3M | Buy |
541,520
+146,439
| +37% | +$15M | 0.23% | 108 |
|
|
2017
Q4 | $38.9M | Buy |
395,081
+249,217
| +171% | +$23.6M | 0.12% | 218 |
|
|
2017
Q3 | $13.7M | Buy |
145,864
+142,867
| +4,767% | +$15.2M | 0.05% | 410 |
|
|
2017
Q2 | $333K | Sell |
2,997
-96,541
| -97% | -$10.2M | ﹤0.01% | 1290 |
|
|
2017
Q1 | $9.77M | Sell |
99,538
-55,295
| -36% | -$5.27M | 0.05% | 499 |
|
|
2016
Q4 | $14.2M | Buy |
+154,833
| New | +$13.3M | 0.08% | 366 |
|
|
2016
Q3 | – | Sell |
-227,267
| Closed | -$18.5M | – | 1052 |
|
|
2016
Q2 | $18.5M | Sell |
227,267
-692,974
| -75% | -$52.8M | 0.12% | 229 |
|
|
2016
Q1 | $65.8M | Buy |
+920,241
| New | +$61.7M | 0.39% | 51 |
|
|
2014
Q3 | – | Sell |
-931,072
| Closed | -$54.6M | – | 734 |
|
|
2014
Q2 | $54.6M | Buy |
931,072
+432,747
| +87% | +$25.3M | 0.62% | 26 |
|
|
2014
Q1 | $28.9M | Buy |
+498,325
| New | +$26.7M | 0.33% | 77 |
|
|
2013
Q4 | – | Sell |
-566,571
| Closed | -$35M | – | 520 |
|
|
2013
Q3 | $35M | Buy |
566,571
+463,977
| +452% | +$27.8M | 0.47% | 37 |
|
|
2013
Q2 | $6.22M | Buy |
+102,594
| New | +$6.11M | 0.1% | 238 |
|
Other funds holding DGX
VCM
VPM
EIG
Balyasny Asset Management's DGX Position: Q1 2026 in Review
Balyasny Asset Management increased its Quest Diagnostics (DGX) stake by 71% in Q1 2026, buying an estimated $234K and bringing the position to 2,898 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #2317.
Balyasny Asset Management first reported a position in DGX in Q2 2013 and has held it in 30 quarters since. The position peaked at $78.3M in Q2 2022. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Balyasny Asset Management held 2,898 shares of Quest Diagnostics worth $568K as of Q1 2026.
- Balyasny Asset Management bought 1,203 Quest Diagnostics shares in Q1 2026, an estimated $234K.
- Quest Diagnostics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2317 holding.
- Balyasny Asset Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 30 quarters since.
- Balyasny Asset Management's Quest Diagnostics position peaked at $78.3M in Q2 2022.
- 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.